Similar Papers

Paper Title
Journal
Date
Author
Abstract C159: ALK signaling primes the DNA damage response allowing exploitation of ATR inhibition in ALK-driven Neuroblastoma
Marcus Borenäs ... Jonatan Gabre
Molecular Cancer Therapeutics | VOL. 22
Marcus Borenäs, et. al.Marcus Borenäs ... Jonatan Gabre
01 Dec 2023
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.
David King ... Sally George
Oncotarget | VOL. 11
David King, et. al.David King ... Sally George
09 Jun 2020
Abstract 2018: Therapeutic benefit of dual ALK and FAK inhibition in neuroblastoma
Seema Chugh ... Chi Chiang Li
Cancer Research | VOL. 82
Seema Chugh, et. al.Seema Chugh ... Chi Chiang Li
15 Jun 2022
Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Jason R Healy ... Jo Lynne Rokita
Pediatric Blood & Cancer | VOL. 67
Jason R Healy, et. al.Jason R Healy ... Jo Lynne Rokita
19 Apr 2020
View more papers

More From: Oncotarget

Paper Title
Journal
Date
Author
Computed tomography-based radiomics and body composition model for predicting hepatic decompensation.
Yashbir Singh ... Bradley J Erickson
Oncotarget | VOL. 15
Yashbir Singh, et. al.Yashbir Singh ... Bradley J Erickson
22 Nov 2024
Retraction: MicroRNA-34a regulates liver regeneration and the development of liver cancer in rats by targeting Notch signaling pathway.
Xiao-Ping Wang ... Xiao-Peng Yuan
Oncotarget | VOL. 15
Xiao-Ping Wang, et. al.Xiao-Ping Wang ... Xiao-Peng Yuan
22 Nov 2024
Retraction: Hyperglycemia via activation of thromboxane A2 receptor impairs the integrity and function of blood-brain barrier in microvascular endothelial cells.
Zhihong Zhao ... Zhan Liu
Oncotarget | VOL. 15
Zhihong Zhao, et. al.Zhihong Zhao ... Zhan Liu
22 Nov 2024
Advancements in cell-penetrating monoclonal antibody treatment.
Sai Pallavi Pradeep ... Raman Bahal
Oncotarget | VOL. 15
Sai Pallavi Pradeep, et. al.Sai Pallavi Pradeep ... Raman Bahal
22 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.